News
Untreatable Lung Cancer Patients Get Breakthrough Treatment
The head of the NHS revealed today that a breakthrough targeted medication treating lung cancer would be made accessible to anybody who qualifies, owing to a new drug deal. Sotorasib is a drug that targets a genetic abnormality known...
News
Exclusive license for Croda to commercialise SSI’s CAF vaccine adjuvants
Croda International Plc, which uses smart science to improve lives, announces that it has entered a strategic collaboration with Statens Serum Institut (“SSI”), the leading Danish Governmental life-science research institute.
Croda’s vaccine adjuvant specialists, based in Denmark, will exclusively manufacture,...
News
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its...
Drug Research
IDT Biologika Collaborates with Exothera to Push Forward the Scale-Up of Viral Vaccines
IDT Biologika, a leading Contract Development and Manufacturing Organization (CDMO) specialized in vaccines, gene and immune therapy and oncolytic viruses, and Exothera S.A. collaborate to develop a large-scale manufacturing process for viral vector-based vaccines. The feasibility study is focussing...
News
CTI Biopharma’s Drug For Bone Marrow Cancer Approved By FDA
The U.S. Food and Medication Administration authorised CTI BioPharma Corp's drug for treating adult patients with a kind of bone marrow cancer who also have a low blood platelet count. Vonjo (pacritinib) belongs to a class of anti-inflammatory drugs...
News
INCOG Biopharma Services completes analytical and quality control testing laboratory & technology transfer suite
INCOG BioPharma Services announces it has completed the construction of its Quality Control testing laboratories, as well as the technology transfer and scale-up suite, at its headquarters in Fishers, Indiana. Shortly after INCOG employees moved into their new offices,...
News
Biocon Biologics to Acquire Viatris Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced that it has entered into a definitive agreement with its partner Viatris Inc. Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris’ biosimilars business to create a unique fully integrated global...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read